On October 10, Tom Lee of Fundstrat joined ‘Closing Bell’ on CNBC to suggest that the S&P can still get to at least 7,000 this year. Tom Lee stated that markets are attempting to balance a few things. He acknowledged that the market is navigating a little blind because of the government shutdown, due to a lack of data, but stressed that the real powerful driver of the equity market and the economy, which is AI, is not affected by this slowdown. He characterized the current trading as a zigzag pattern but maintained a bullish outlook into year-end, given the seasonal period. He reiterated that recent pullbacks are being bought, suggesting that even if the market is weak today, it could rally tomorrow.
Lee conceded that the markets are less skeptical than they were in April, August, and September, visible in both positioning and AI sentiment, meaning it is fair to say that the markets have priced in more good news. However, he argued that the AI story is actually strengthening based on his conversations with companies and investors. He suggested that the payback for AI has improved in the last quarter or so. He believes this improvement is helping actually create demand for spending, and that the market may be underestimating the sort of profit creation coming from AI, which gives the story still legs. He acknowledged that the data is mixed and that they don’t really know the full picture without government data.
That being said, we’re here with a list of the 14 most promising stocks under $100.
Our Methodology
We sifted through the Finviz stock screener to compile a list of the most promising stocks that were trading below $100 as of October 7. We then selected the 14 stocks that were the most popular among elite hedge funds and that analysts were bullish on. The stocks are ranked in ascending order of the number of hedge funds that have stakes in them, as of Q2 2025.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).
14 Most Promising Stocks Under $100
14. Flex Ltd. (NASDAQ:FLEX)
Share Price as of October 7: $57.72
Number of Hedge Fund Holders: 55
Flex Ltd. (NASDAQ:FLEX) is one of the most promising stocks under $100. On October 8, BofA raised the firm’s price target on Flex to $65 from $58, while keeping a Buy rating on the shares. The company’s long-term goal is to achieve a 20% CAGR for data center revenue, and it is currently exceeding this target. BofA is raising its financial estimates for the company for this reason as well.
Flex achieved record results for FQ1 2026, reporting revenues of $6.6 billion, which was an increase of 4% year-over-year. The company’s adjusted EPS was $0.72, marking a record FQ1 performance and a rise of more than 40% from the prior year. Primary growth comes from the Data Center business, which is expected to make ~$6.5 billion in revenue for FY2026 and meet its annual growth target of 35%, representing 25% of total company revenue.
Flex is positioned as the sole provider offering both end-to-end cloud IT integration and a full power and cooling portfolio at scale. This includes integrated solutions like vertically integrated IT hardware, custom rack assembly, direct-to-chip liquid cooling technology on the cloud side, and a full power stack featuring modular Power Pods on the power side.
Flex Ltd. (NASDAQ:FLEX) is a technology company that provides tech innovation, supply chain, and manufacturing solutions to various industries through two different segments: Flex Agility Solutions/FAS and Flex Reliability Solutions/FRS.
13. Teva Pharmaceutical Industries Limited (NYSE:TEVA)
Share Price as of October 7: $19.91
Number of Hedge Fund Holders: 57
Teva Pharmaceutical Industries Limited (NYSE:TEVA) is one of the most promising stocks under $100. On October 9, BofA raised the firm’s price target on Teva to $24 from $22, while keeping a Buy rating on the shares. This sentiment was posted as BofA analyzed Q3 2025 drug pricing & sales volume and company comments, and concluded that the firm anticipates no significant Q3 EPS surprises (beats or misses) and no changes to 2026 financial outlooks for the biopharma companies that it covers.
Earlier in Q2 2025, Teva Pharmaceutical marked its 10th consecutive quarter of year-over-year revenue growth as it executes its Pivot to Growth Strategy. The company is targeting a 30% operating profit margin by 2027. Total revenues for the quarter were $4.2 billion, which was an increase of ~1% in local currency when excluding revenues from the Japan Business Venture, which was divested.
Growth was primarily driven by the innovative portfolio, which collectively grew by ~26%. Based on this performance, Teva increased its 2025 revenue outlook for its key innovative products. AUSTEDO revenues were $498 million globally in Q2, up ~19% globally and ~22% in the US, with the 2025 revenue outlook raised to $2,000 to $2,050 million. AJOVY global revenues were $155 million, up ~31%, with the outlook increased to $630 to $640 million. UZEDY revenues were $54 million, accelerating by ~120%, with the outlook raised to $190 to $200 million.
Teva Pharmaceutical Industries Limited (NYSE:TEVA) is a healthcare company that develops, manufactures, markets, and distributes generic and other medicines & biopharmaceutical products.
Hedge Fund Resource Center